Gaucher Disease: Review and Perspectives on Treatment

  • Mario A. Cabrera-Salazar
  • John A. Barranger

Gaucher disease is an autosomal recessive disease and the most prevalent lysosomal storage disorder with an incidence of about 1 in 20,000 live births. Despite the fact that GD consists of a phenotypic spectrum with varying degrees of severity, it has been subdivided in three subtypes according to the presence or absence of neurological involvement. It is also the most common genetic disease among Ashkenazi Jews, with a carrier frequency of 1 in 10 (Barranger and Ginns, 1989). This panethnic disease involves many organ systems (summarized in Table 1). The disease is highly variable as a consequence of modifier genes whose identities remain unknown. However, Gaucher disease is progressive in all of its forms. Genotype/ phenotype correlations are not reliable with the exception that the N370S allele, even if present in a single dose, protects from a neurodegenerative course (Tsuji et al., 1988).


Enzyme Replacement Therapy Fabry Disease Gauche Disease Equine Infectious Anemia Virus Metachromatic Leukodystrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Achord, D., Brot, F., Gonzalez-Noriegam, A., Sly, W., Stahl, P.  (1977) Human betaglucuronidase. II. Fate of infused human placental beta-glucuronidase in the rat. Pediatr Res. 11:816.CrossRefPubMedGoogle Scholar
  2. Aharon-Peretz, J., Rosenbaum, H., Gershoni-Baruch, R. (2004) Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med. 351:1972CrossRefPubMedGoogle Scholar
  3. Ashwell, G., Kawasaki, T. (1978) A protein from mammalian liver that specifically binds galactose-terminated glycoproteins. Methods Enzymol. 50:287.CrossRefPubMedGoogle Scholar
  4. Ashwell, G., Morell A.G. (1974) The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol. 99.Google Scholar
  5. Bahnson, A.B., Dunigan, J.T., Baysal, B.E., Mohney, T., Atchison, R.W., Nimgaonkar, M.T., Ball, E.D., Barranger, J.A. (1995) Centrifugal enhancement of retroviral mediated gene transfer. J Virol Methods. 54:131CrossRefPubMedGoogle Scholar
  6. Barranger, J.A., Ginns, E. (1989) Glucosylceramide lipidoses: Gaucher disease. In: Scriver,C.R., Sly, W.S., Valle, D. (Eds.), The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, pp. 1677-1698.Google Scholar
  7. Barranger, J.A., Pentchev, P.G., Furbish, F.S., Steer, C.J., Jones, E.A., Brady, R.O. (1978) Studies of lysosomal function: I. Metabolism of some complex lipids by isolated hepatocytes and Kupffer cells. Biochem Biophys Res Commun. 83:1055.CrossRefPubMedGoogle Scholar
  8. Barton, N.W., Brady, R.O., Dambrosia, J.M., Di Bisceglie, A.M., Doppelt, S.H., Hill, S.C., Mankin, H.J., Murray, G.J., Parker, R.I., Argoff, C.E., et al. (1991) Replacement therapy for inherited enzyme deficiency: Macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 324:1464-1470.PubMedGoogle Scholar
  9. Bembi, B., Ciana, G., Mengel, E., Terk, M.R., Martini, C., Wenstrup, R.J. (2002) Bone complications in children with Gaucher disease. Br J Radiol. 75 Suppl 1:A37-44.PubMedGoogle Scholar
  10. Boklan, B.F., Sawitsky, A. (1976). Factor IX deficiency in Gaucher's disease. An in vitro phenomenon. Arch Intern Med. 136:489-92.CrossRefPubMedGoogle Scholar
  11. Boot, R.G.,Verhoek, M., de Fost, M., Hollak, C.E., Maas, M., Bleijlevens, B., van Breemen, M.J., van Meurs, M., Boven, L.A., Laman, J.D., Moran, M.T., Cox, T.M., Aerts, J.M. (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood. 103:33CrossRefPubMedGoogle Scholar
  12. Brady, R.O., Barranger, J.A., Gal, A.E., Pentchev, P.G.,Furbish, F.S. (1980). Status of enzyme replacement therapy for Gaucher disease. Birth Defects Orig Artic Ser. 16:361PubMedGoogle Scholar
  13. Brady, R.O., Kanfer, J.N., Bradley, R.M., Shapiro, D. (1966) Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher’s disease. J Clin Invest. 45:1112CrossRefPubMedGoogle Scholar
  14. Brady R.O., Pentev, P.G., Gal, A.E., Hibbert, S.R., Dekeban, A.S. (1974) Replacement therapy for inherited enzyme deficiency: Use of purified glucocerebrosidase in Gaucher’s disease. N Engl J Med. 291:989-993.PubMedCrossRefGoogle Scholar
  15. Cabrera-Salazar, M.A., O’Rourke, E., Henderson, N., Wessel, H., Barranger, J.A. (2004) Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clin Chim Acta. 344:101-107.CrossRefPubMedGoogle Scholar
  16. Chang-Lo, M., Yam, L.T., Rubenstone, A.I. (1967) Gaucher’s disease. Am J Med Sci 254:303-315.CrossRefPubMedGoogle Scholar
  17. Charrow, J., Esplin, J.A., Gribble, T.J., Kaplan, P., Kolodny, E.H., Pastores, G.M., Scott, C.R., Wappner, R.S., Weinreb, N.J., Wisch, J.S. (1998) Gaucher disease: Recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med. 158:1754-1760.CrossRefPubMedGoogle Scholar
  18. Ciana, G., Martini, C., Leopaldi, A., Tamaro, G., Katouzian, F., Ronfani, L., Bembi, B. (2003) Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int. 72:185-189CrossRefPubMedGoogle Scholar
  19. Consiglio, A., Gritti, A., Dolcetta, D., Follenzi, A., Bordignon, C.,Gage, F.H., Vescovi, A.L., Naldini, L. (2004) Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors. Proc Natl Acad Sci USA. 101:14835-14840.CrossRefPubMedGoogle Scholar
  20. Consiglio, A., Quattrini, A., Martino, S., Bensadoun, J.C., Dolcetta, D., Trojani, A., Benaglia, G., Marchesini, S., Cestari, V., Oliverio, A., Bordignon, C., Naldini, L. (2001) In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: Correction of neuropathology and protection against learning impairments in affected mice. Nat Med. 7:310-316.CrossRefPubMedGoogle Scholar
  21. Cox, T., Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebicek, M., Platt F.M., Butters, T.D., Dwek, R., Moyses, C., Gow, I., Elstein, D., Zimran, A. (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 355:1481-1485.CrossRefPubMedGoogle Scholar
  22. De Duve, C. (1969). The lysosome in retrospect. In: J.T. Dingle, H.B. Fell (Eds.) Lysosomes in Biology and Pathology, Amsterdam: North-Holland, Vol. 1, pp. 3-40.Google Scholar
  23. De Duve, C., Pressman, B.C., Gianetto, R., Wattiaux, R., Appelmans, F. (1955) Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J. 60:604-617.PubMedGoogle Scholar
  24. Enquist, I.B., Nilsson, E., Ooka, A., Mansson, J.E., Olsson, K., Ehinger, M., Brady, R.O., Richter, J., Karlsson, S. (2006) Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci USA. 103:13819-13824.CrossRefPubMedGoogle Scholar
  25. Erickson, A.H., Ginns, E.I., Barranger, J.A. (1985) Biosynthesis of the lysosomal enzyme glucocerebrosidase. J Biol Chem. 260:14319-14324.PubMedGoogle Scholar
  26. European Public Assessment Report (EPAR). Zavesca [miglustat]. (2002) Committee for Proprietary Medicinal Products EPAR. CPMP/3795/02. London, England: The European Agency for the Evaluation of Medicinal Products. humandocs/Humans/EPAR/zavesca/zavesca.htm.
  27. Fratantoni, J.C., Hall, C.W., Neufeld, E.F. (1968) Hurler and Hunter syndromes: Mutual correction of the defect in cultured fibroblasts. Science. 162:570-572.CrossRefPubMedGoogle Scholar
  28. Fredrickson, D.S., Sloan, H.R. (1978) In: Stanburg, J.B. Wyngaarden, J.B. Fredrickson, D.S. (Eds.) The Metabolic Basis of Inherited Disease. 4th ed. New York: McGraw-Hill.Google Scholar
  29. Furbish, F.S., Blair, H.E., Shiloach, J., Pentchev, P.G., Brady, R.O. (1977) Enzyme replacenment therapy in Gaucher disease. Large Scale purification of glucocerebrosidase suitable for human administration. Proc Natl Acad Sci USA. 74:3560CrossRefPubMedGoogle Scholar
  30. Furbish, F.S., Steer, C.J., Barranger, J.A., Jones, E.A., Brady, R.O. (1978) The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells. Biochem Biophys Res Commun. 81:1047-1053.CrossRefPubMedGoogle Scholar
  31. Ginns, E.I., Choudary, P.V., Martin, B.M., Winfield, S., Stubblefield, B., Mayor, J., Merkle-Lehman, D., Murray, G.J., Bowers, L.A., Barranger, J.A. (1984) Isolation of cDNA clones for human beta-glucocerebrosidase using the lt11 expression system. Biochem Biophys Res Commun. 123:574-580.CrossRefPubMedGoogle Scholar
  32. Goldblatt, J., Sacks, S., Beighton, P. (1978) The orthopedic aspects of Gaucher disease. Clin Orthop. 137:208-214.PubMedGoogle Scholar
  33. Grabowski, G.A., Barton, N.W., Pastores, G., Dambrosia, J.M., Banerjee, T.K., McKee, M.A., Parker, C. , Schiffmann, R., Hill, S.C., Brady, R.O. (1995) Enzyme therapy in Type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 122:33-39.PubMedGoogle Scholar
  34. Halleen, J.M., Ylipahkala, H., Alatalo, S.L., Janckila, A.J., Hekkinen, J.E., Suominen, H., Cheng, S., Vaananen, H.K. (2002) Serum Tartrate-Resistant Acid Phosphatase 5b, but not 5a, Correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int. 71:20-25.CrossRefPubMedGoogle Scholar
  35. Hannun, Y.A., Bell, R.M. (1987). Lysosphingolipids inhibit protein kinase C: Implications for the sphingolipidoses. Science. 235:670-674.CrossRefPubMedGoogle Scholar
  36. Hollak, C.E., Evers, L., Aerts, J.M.,van Oers, M.H. (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis. 23:201-212.CrossRefPubMedGoogle Scholar
  37. Hollak, C.E., van Weely, S., van Oers, M.H., Aerts, J.M. (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 93:1288.CrossRefPubMedGoogle Scholar
  38. Hong, C.M., Ohashi, T., Yu, X.J., Weiler, S., Barranger, J.A. (1990) Sequence of two alleles responsible for Gaucher disease. DNA Cell Biol. 9:233-41.CrossRefPubMedGoogle Scholar
  39. Horowitz, M., Wilder, S., Horowitz, Z., Reiner, O., Gelbart, T., Beutler, E. (1989) The human glucocerebrosidase gene and pseudogene: Structure and evolution. Genomics. 4:87-96.CrossRefPubMedGoogle Scholar
  40. Hultberg, B., Isaksson, A., Sjoblod, S., Ockerman, P.A. (1980) Acid hydrolases in serum from patients with lysosomal disorders. Clin Chim Acta. 100:33-38.CrossRefPubMedGoogle Scholar
  41. Ikeda, Y., Collins, M.K., Radcliffe, P.A., Mitrophanous, K.A.,Takeuchi, Y. (2002) Gene transduction efficiency in cells of different species by HIV and EIAV vectors. Gene Ther. 9:932-938.CrossRefPubMedGoogle Scholar
  42. James, S.P., Stromeyer, F.W., Chang, C.S.C., Barranger, J.A. (1981) Liver abnormalities in Gaucher’s Disease. Gastroenterology 80:126-133.PubMedGoogle Scholar
  43. Kattlove, H.E., Williams, J.C., Gaynor, E., Spivack, M., Bradley, R.M., Brady, R.O. (1969) Gaucher cells in chronic myelocytic leukemia: An acquired abnormality. Blood. 33:379-390.PubMedGoogle Scholar
  44. Kaye, E.M., Ullman, M.D., Wilson, E.R., Barranger, J.A. (1986) Type 2 and type 3 Gaucher disease: a morphological and biochemical study. Ann Neurol. 20:223-230CrossRefPubMedGoogle Scholar
  45. Kim, E.Y., Hong, Y.B., Lai, Z., Kim, H.J., Cho, Y.H, Brady, R.O., Jung, S.C. (2004) Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: Implications for gene therapy of Gaucher disease. Biochem Biophys Res Commun. 318:381-390.CrossRefPubMedGoogle Scholar
  46. Lieb, H. (1924) Der zucker im cerebrosid der milz bei der Gaucher krankheit. HoppeSeyler’s Z Physiol Chem. 271:211.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Mario A. Cabrera-Salazar
    • 1
  • John A. Barranger
    • 2
  1. 1.Genetic Diseases ScienceGenzyme CorporationFraminghamUSA
  2. 2.Department of Human GeneticsUniversity of PittsburghPittsburghUSA

Personalised recommendations